OPRX vs. PHR, WLDN, STGW, PLTK, TIXT, TASK, PRG, UPBD, NEO, and CRTO
Should you be buying OptimizeRx stock or one of its competitors? The main competitors of OptimizeRx include Phreesia (PHR), Willdan Group (WLDN), Stagwell (STGW), Playtika (PLTK), Telus Digital (TIXT), TaskUs (TASK), Aaron's (PRG), Upbound Group (UPBD), NeoGenomics (NEO), and Criteo (CRTO). These companies are all part of the "business services" industry.
OptimizeRx vs. Its Competitors
Phreesia (NYSE:PHR) and OptimizeRx (NASDAQ:OPRX) are both small-cap business services companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, profitability, earnings, institutional ownership and dividends.
92.1% of Phreesia shares are owned by institutional investors. Comparatively, 76.5% of OptimizeRx shares are owned by institutional investors. 5.5% of Phreesia shares are owned by insiders. Comparatively, 5.6% of OptimizeRx shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
OptimizeRx has lower revenue, but higher earnings than Phreesia. Phreesia is trading at a lower price-to-earnings ratio than OptimizeRx, indicating that it is currently the more affordable of the two stocks.
Phreesia has a net margin of -5.35% compared to OptimizeRx's net margin of -9.42%. OptimizeRx's return on equity of 4.50% beat Phreesia's return on equity.
In the previous week, Phreesia had 2 more articles in the media than OptimizeRx. MarketBeat recorded 4 mentions for Phreesia and 2 mentions for OptimizeRx. OptimizeRx's average media sentiment score of 1.00 beat Phreesia's score of 0.01 indicating that OptimizeRx is being referred to more favorably in the news media.
Phreesia currently has a consensus price target of $33.85, suggesting a potential upside of 46.46%. OptimizeRx has a consensus price target of $13.39, suggesting a potential downside of 32.52%. Given Phreesia's stronger consensus rating and higher possible upside, research analysts clearly believe Phreesia is more favorable than OptimizeRx.
Phreesia has a beta of 0.68, meaning that its share price is 32% less volatile than the S&P 500. Comparatively, OptimizeRx has a beta of 1.25, meaning that its share price is 25% more volatile than the S&P 500.
Summary
Phreesia beats OptimizeRx on 9 of the 17 factors compared between the two stocks.
Get OptimizeRx News Delivered to You Automatically
Sign up to receive the latest news and ratings for OPRX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding OPRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
OptimizeRx Competitors List
Related Companies and Tools
This page (NASDAQ:OPRX) was last updated on 10/21/2025 by MarketBeat.com Staff
Free OPRX Stock Alerts